Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women
Status:
Completed
Trial end date:
2017-09-06
Target enrollment:
Participant gender:
Summary
Tuberculosis (TB) is a leading cause of death among HIV-infected persons in low-income
settings and can be a serious complication for HIV-infected pregnant women and their infants.
Isoniazid (INH) preventive therapy (IPT) is effective in preventing TB infection in
HIV-infected adults, but the safety of IPT in pregnant women is unknown. This study evaluated
the safety of IPT among HIV-infected pregnant women.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)